Top Page
Shandong Weigao Group Medical Polymer Co
(OTC:1066)
Shandong Weigao Group Medical Polymer Co (1066) vs. iShares MSCI Hong Kong ETF (EWH)
Shandong Weigao Group Medical Polymer Co Business Overview & Revenue Model
Shandong Weigao Group Medical Polymer Co Financial Statement Overview
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 13.10B | 13.09B | 13.23B | 13.62B | 13.15B | 11.62B |
| Gross Profit | 6.46B | 6.58B | 6.64B | 7.31B | 7.35B | 6.46B |
| EBITDA | 3.08B | 3.14B | 3.55B | 4.38B | 3.75B | 3.09B |
| Net Income | 1.97B | 2.07B | 2.00B | 2.76B | 2.28B | 2.09B |
Balance Sheet | ||||||
| Total Assets | 36.14B | 34.76B | 33.67B | 33.20B | 30.37B | 27.34B |
| Cash, Cash Equivalents and Short-Term Investments | 9.65B | 8.32B | 7.33B | 7.49B | 7.13B | 6.14B |
| Total Debt | 5.51B | 4.19B | 4.17B | 4.49B | 4.14B | 4.32B |
| Total Liabilities | 10.45B | 9.42B | 9.68B | 9.75B | 9.46B | 8.95B |
| Stockholders Equity | 24.10B | 23.75B | 22.45B | 21.67B | 19.27B | 17.55B |
Cash Flow | ||||||
| Free Cash Flow | 2.05B | 2.19B | 2.11B | 1.10B | 1.92B | 1.70B |
| Operating Cash Flow | 2.65B | 2.79B | 2.80B | 2.21B | 3.04B | 2.70B |
| Investing Cash Flow | -2.21B | -1.10B | -1.39B | -2.57B | -1.48B | 423.22M |
| Financing Cash Flow | -500.93M | -1.60B | -2.16B | -1.02B | -547.92M | -1.79B |
Shandong Weigao Group Medical Polymer Co Technical Analysis
Shandong Weigao Group Medical Polymer Co Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
83 Outperform | €10.68B | 17.58 | 23.40% | 2.84% | 6.51% | 4.85% | |
74 Outperform | €2.12B | 13.75 | 3.76% | 7.19% | 21.39% | -0.57% | |
74 Outperform | €5.18B | 10.92 | 17.42% | 3.76% | 6.87% | 18.37% | |
72 Outperform | HK$26.44B | 45.76 | 24.57% | 0.67% | 13.58% | 24.59% | |
70 Neutral | HK$5.29B | 25.57 | 10.31% | ― | 14.06% | 3.02% | |
68 Neutral | HK$23.92B | 11.35 | 8.34% | 4.57% | 0.74% | 2.13% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
Shandong Weigao Group Medical Polymer Co Corporate Events
Shandong Weigao Group Medical Polymer Company Limited has announced the postponement of its Extraordinary General Meeting (EGM) originally scheduled for 17 December 2025, now rescheduled to 19 December 2025 due to work arrangement coordination. The change also affects the book closure period and record date for shareholders, with the register of members for H Shares closed from 16 December to 19 December 2025, and the record date set for 19 December 2025. These adjustments ensure shareholders have the opportunity to attend and vote at the rescheduled EGM.
Shandong Weigao Group Medical Polymer Company Limited has announced an extraordinary general meeting to be held on December 17, 2025, to discuss and approve several key resolutions. These include the approval of the Purchase Framework Agreement and the Logistic Support Services Framework Agreement, the reappointment of Mr. Li Qiang as an independent non-executive director, and a change in the company type. These resolutions are expected to impact the company’s operational strategies and governance structure.
Shandong Weigao Group Medical Polymer Company Limited has announced the renewal of its existing continuing connected transactions through Supplemental Agreements with Weigao Holding and its subsidiaries. These agreements involve revising the annual cap for 2025 and extending the terms of the CCT Agreements to 2027. The transactions, which are subject to certain reporting and approval requirements under the Listing Rules, reflect the company’s strategic efforts to maintain and strengthen its business relationships and operational framework.
Shandong Weigao Group Medical Polymer Company Limited has announced the formation of a joint venture with PT Oneject Indonesia, named Oneject Wego Medical, to manufacture and sell medical consumables in Indonesia. This strategic move aims to tap into the Indonesian market by leveraging local production capabilities and reducing reliance on imports, thereby expanding Weigao’s overseas market presence and customer base.
Shandong Weigao Group Medical Polymer Company Limited reported a 2.6% year-on-year revenue increase for the third quarter, reaching approximately RMB3.26 billion. The orthopedic, interventional, and blood management segments saw significant growth, while pharma packaging and medical devices faced challenges due to pricing pressures from government policies, impacting overall sales revenue growth.
Shandong Weigao Group Medical Polymer Co., Ltd. has announced a transaction involving its subsidiary, WEGO Prefills. Weigao Blood Purification will acquire 100% equity interest in WEGO Prefills, and in exchange, will issue Consideration Shares to the shareholders. This transaction may lead to Weigao Blood Purification becoming a non-wholly-owned subsidiary of the company, potentially affecting its financial consolidation. The transaction is significant under the Listing Rules, requiring reporting and shareholder approval due to its classification as a major and connected transaction.
Shandong Weigao Group Medical Polymer Co has made an overseas regulatory announcement in accordance with the disclosure requirements of the Hong Kong Stock Exchange. The announcement, published on the Shanghai Stock Exchange’s website, is part of the company’s compliance with relevant Chinese regulations, highlighting its commitment to transparency and adherence to market rules.
Shandong Weigao Group Medical Polymer Company Limited announced a potential transaction involving its subsidiary, Weigao Blood Purification, which intends to acquire 100% equity interest in WEGO Prefills Pharmaceutical Packaging Co., Ltd. This acquisition aims to create business synergies and expand the overall business scope of the Group. If completed, the transaction may be classified as a major and connected transaction under the Hong Kong Listing Rules, necessitating further disclosures.
Shandong Weigao Group Medical Polymer Company Limited held an Extraordinary General Meeting on October 17, 2025, where all proposed resolutions were approved by shareholders. Key decisions included the approval of the 2025 H Share Incentive Scheme, the distribution of an interim dividend, and several amendments to the company’s articles of association. These resolutions are expected to enhance shareholder value and align the company’s governance structure with its strategic goals.
Shandong Weigao Group Medical Polymer Co. has announced an interim dividend of RMB 0.0969 per share for the six months ending June 30, 2025, with a payment date set for November 21, 2025. This announcement reflects the company’s financial performance and commitment to shareholder returns, with implications for both domestic and international investors regarding withholding tax rates.
Shandong Weigao Group Medical Polymer Company Limited has announced the composition of its board of directors, highlighting the roles and functions of each member. This announcement provides clarity on the company’s governance structure, potentially impacting its strategic direction and stakeholder confidence.
Shandong Weigao Group Medical Polymer Company Limited announced an interim cash dividend of RMB 0.0969 per share for the six months ending June 30, 2025. The announcement includes a change in the date of the extraordinary general meeting, record date, and book closure period, with the payment date set for November 21, 2025. This dividend declaration reflects the company’s financial performance and commitment to returning value to shareholders, potentially impacting investor sentiment and market positioning.
Shandong Weigao Group Medical Polymer Co., Ltd. has announced an extraordinary general meeting to discuss the approval and adoption of the 2025 H Share Incentive Scheme, which aims to grant share awards and manage the issuance of shares up to 4.5% of the company’s total shares. Additionally, the company plans to distribute an interim dividend and reappoint Mrs. Meng Hong as an independent non-executive director, reflecting its commitment to shareholder value and governance.
Shandong Weigao Group Medical Polymer Company Limited has announced a rescheduling of its extraordinary general meeting (EGM) from October 16, 2025, to October 17, 2025, to allow more time for finalizing the circular to be sent to shareholders. The book closure period for determining shareholders’ entitlement to attend and vote at the EGM has also been adjusted, impacting the timeline for share transfers and dividend entitlements.
Shandong Weigao Group Medical Polymer Company Limited announced proposed amendments to its Articles of Association to align with recent legal and regulatory changes, including the flexibility to manage treasury shares and facilitate electronic voting in shareholder meetings. Additionally, the company plans to implement full circulation of its H shares, converting 48,300,000 unlisted shares into H shares, pending necessary approvals, which could enhance liquidity and market presence.
Shandong Weigao Group Medical Polymer Company Limited announced the resignation of Ms. Yan Xia from her roles as vice chairman and non-executive director, effective 8 October 2025, as she pursues personal development opportunities. The company assured stakeholders that her departure will not affect the board’s statutory quorum or the normal operations of the company, and expressed gratitude for her contributions.